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ABSTRACT
Docetaxel is the chemotherapeutic choice for metastatic hormone-refractory 
prostate cancer, however, it only marginally improves the survival rate. The purpose 
of the present study was to examine if a peptide targeting the cellular scaffold 
protein PCNA could improve docetaxel’s efficacy. We found that docetaxel given in 
combination with a cell penetrating peptide containing the AlkB homolog 2 PCNA 
interacting motif (APIM-peptide), reduced the prostate volume and limited prostate 
cancer regrowth in vivo in the immunocompetent transgenic adenocarcinoma model 
of prostate cancer (TRAMP). In accordance with this, we found that the APIM-peptide 
enhanced the efficacy of docetaxel in vitro. Gene expression analysis on prostate 
cancer cell lines indicated that the combination of docetaxel and APIM-peptide alters 
expression of genes involved in cellular signaling, apoptosis, and prostate cancer 
development. These changes were not detected in single agent treated cells. Our 
results suggest that targeting PCNA and thereby affecting multiple cellular pathways 
simultaneously has the potential to improve docetaxel therapy of advanced prostate 
cancer.
INTRODUCTION
Prostate cancer (PCa) is the second most common 
form of cancer among men worldwide, and ranks as 
the fifth leading cause of cancer death [1]. Generally, 
chemotherapy treatment remains the last line of therapy 
for hormone-refractory and metastatic PCa, where 
docetaxel in combination with prednisone is the most 
common regimen [2]. Docetaxel’s primary mode of 
action is to inhibit microtubule disassembly by binding 
to β-tubulin, leading to inhibition of multiple cellular 
processes including vesicular transport, transcription factor 
trafficking, cellular signaling, and inhibition of mitotic 
cell cycle progression. PCa cells in vivo do not necessarily 
proliferate very rapidly, and promotion of apoptosis and 
inhibition of androgen receptor transcriptional activity are 
important non-mitotic effects suggested to be the main 
reasons why taxanes are the only class of cytotoxic agents 
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to prolong survival in PCa [3]. Still, docetaxel treatment 
is not curative because drug resistance develops; novel 
treatment options that improve outcome in advanced PCa 
are therefore in demand. Combining docetaxel with novel 
drugs that complement its mode of action could potentially 
delay the development of resistance. Inhibition of kinase 
pathways such as the PI3K/Akt/mTOR and mitogen-
activated protein kinase (MAPK) pathways, frequently 
found to be upregulated in PCa, are suggested strategies 
[4, 5].
PCNA (proliferating cell nuclear antigen), an 
essential scaffold protein best known for its roles in DNA 
replication and DNA repair, has emerged in the last decade 
as an interesting drug target (reviewed in [6, 7]). Recently, 
it has become evident that PCNA also functions as a 
scaffold outside the nucleus and is important for regulation 
of vital cellular mechanisms such as apoptosis [8, 9], 
immune invasion in cancer cells [10, 11], glycolysis [12], 
and cellular signaling involving the PI3K/Akt/mTOR and 
MAPK pathways [13]. These newly discovered functions 
of PCNA are cell cycle independent (for a recent review 
see [14]). 
PCNA may potentially interact with more than 
500 cellular proteins, as these contain either of the two 
identified PCNA-interacting motifs, the PCNA-interacting 
peptide (PIP)-box [15] and the AlkB homologue 2 
PCNA-interacting motif (APIM) [16]. The PIP-box 
is found in essential proteins involved in replication, 
while several proteins involved in DNA repair and DNA 
damage tolerance mechanisms contain APIM [16–20]. 
Additionally, multiple proteins including kinases and 
regulators of apoptosis, contain putative APIM or PIP-box 
motifs, which suggests that targeting PCNA may impair 
multiple cellular pathways simultaneously [16]. It has 
been shown that targeting PCNA with an APIM-peptide 
impaired cellular defense mechanisms and major signaling 
pathways, with the consequence of hypersensitivity of 
cancer cells to chemotherapies in vitro and in vivo [13, 21, 
22]. Interestingly, normal cells were much less affected, 
and the peptide had low overall cytotoxicity in vivo. 
Here, we raise the question as to whether targeting 
PCNA could improve the efficacy of docetaxel in the 
spontaneous mouse TRAMP PCa model. This model 
was selected because it recapitulates both the histological 
characteristics and the progressive development of human 
PCa towards androgen-insensitivity [23], and it is regarded 
as a clinically relevant in vivo model to evaluate novel 
therapeutic strategies. PCa growth in the TRAMP model 
was monitored using magnetic resonance imaging (MRI) 
in vivo. Interestingly, APIM-peptide in combination with 
docetaxel reduced the tumor regrowth rate compared with 
docetaxel only, and vehicle treated mice. The combination 
also reduced growth of four PCa cell lines, one established 
from a TRAMP-mouse, and three from human PCa. 
Microarray analysis of the three human cell lines treated 
with the combination of docetaxel and APIM-peptide 
showed that the response was different in an androgen-
insensitive (PC3 and Du145) compared with androgen-
sensitive (LNCaP) background. However, expression 
of multiple genes commonly dysregulated in PCa was 
changed in the androgen-insensitive cells, and several 
of these support the anti-cancer activity observed in the 
TRAMP mice.
RESULTS
APIM-peptide targeting PCNA reduces the 
regrowth rate of docetaxel treated prostate 
cancer in vivo
We investigated whether an increased anti-cancer 
effect could be observed in vivo in the TRAMP model 
of PCa by combining docetaxel with the PCNA targeting 
APIM-peptide. MRI was used to determine prostate 
volume immediately before the first treatment (day 0), 
and again at days 7, 21, and 28 (Figure 1A and B). A 
significant increase in the relative prostate volume was 
observed in vehicle treated mice at day 7, but not in the 
docetaxel or the combination treated groups, indicating an 
effect of both treatments (Figure 1A). On day 7, docetaxel 
and combination groups showed similar drug responses 
based on tumor volumes. By day 21 the combination 
group showed a trend towards slower tumor regrowth 
compared with both vehicle and docetaxel groups, 
and this trend was maintained at day 28. At day 21, a 
significant difference in prostate volume between vehicle 
and docetaxel, and between vehicle and combination 
groups was observed. Two mice in the vehicle group were 
terminated due to unacceptable tumor burden at day 21. 
By day 28 there was only a significant difference between 
combination and vehicle groups, suggesting that the 
docetaxel group experienced increased cancer regrowth 
compared to the combination group. Additionally, the 
combination treatment led to a more uniform response 
across the individual mice (Figure 1A), i.e. the spread of 
the data was greater for docetaxel treatment alone. Initial 
dose-response studies supported reduced relative prostate 
volume in combination groups compared to docetaxel 
groups (Supplementary Figure 1). As previous studies 
have indicated low or no single agent efficacy and low 
toxicity of the APIM-peptide in various murine cancer 
models [21, 22] (and unpublished), we did not include an 
APIM-peptide single agent group in this study. The low 
single agent activity of the APIM-peptide implies that the 
increased effect of the combination treatment compared 
with docetaxel alone is likely synergistic.
There was no significant difference between 
absolute prostate volumes between any of the groups 
at day 0, whereas by day 28, combination treated mice 
were significantly smaller than vehicle treated. Thus, 
response to therapy was not influenced by variations in 
starting prostate volume (Figure 1B, Supplementary 
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Figure 1B). Cell proliferation analysis with Ki67 staining 
on TRAMP prostate tissue at day 28 indicated slightly 
reduced proliferation in treated prostates compared to 
vehicle treated prostates, however, there was no significant 
difference between the groups (Supplementary Figure 2). 
The main prostate regrowth in the docetaxel group 
occurred from day 7 to day 21, and then stagnated from day 
21 to day 28, likely explaining why no difference between 
docetaxel and combination groups could be detected at 
the end point. The combination treated mice did not have 
higher weight loss than the docetaxel only treated mice 
(data not shown), suggesting that APIM-peptide increased 
the efficacy of docetaxel without reducing the well-being 
of the mice. This is in accordance with observations in 
Figure 1: Reduced regrowth rates of prostate cancers in mice when combining APIM-peptide with standard docetaxel 
treatment. (A) Prostate volumes at day 7, 21 and 28 after treatment relative to day 0 (day of treatment). Mice were treated on day 0 with 
vehicle (0.14% (V/V) ethanol in PBS (n = 7 on day 7 and 21, n = 5 day on day 28, grey symbols), docetaxel (3 mg/kg, 1 dose on day 0, 
n = 7, blue symbols) and docetaxel in combination with APIM-peptide (docetaxel (3 mg/kg) and APIM-peptide (6 mg/kg), 1 dose on day 
0, APIM-peptide (6 mg/kg) on days 2 and 3, n = 5, black symbols). Each individual mouse is represented by a different symbol and color 
denotes treatment group. The average ± S.E.M. are displayed with bars in each group. The red line represents the prostate volume before 
treatment at day 0. Statistical significance/p-values were calculated by an unpaired, two-tailed student t-test. Prostate volumes of the two 
sacrificed mice from the vehicle group on day 21 are included in the average weight on day 28 as they represent a minimum. p < 0.05, *p < 
0.005**. (B) Absolute prostate volumes of individual mice are shown for day 0, closed circles, and day 28 (day 21 for mice 2 and 7, vehicle 
group), open circles. Different colours denote the different treatment groups. The shaded area allows visualization of the absolute prostate 
growth across the group. Symbols corresponding to each individual mouse in 1A are shown below the individual mouse number.
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other in vivo studies with APIM-peptides in combination 
with DNA damaging chemotherapeutics [13, 21, 22]. 
APIM-peptide potentiates the efficacy of 
docetaxel in prostate cancer cell lines and 
modifies the gene expression
Different cancer cell lines, from a variety of tissue 
origins, have different sensitivity against the APIM-
peptide [21, 22]. In general, cancer cell lines are more 
sensitive than normal cell lines, and primary cancer cells 
are more sensitive than primary normal cells. Here, we 
examined whether APIM-peptide could enhance the 
growth inhibitory efficacy of docetaxel in two androgen-
sensitive (LNCaP and TRAMP-C1) and two androgen-
insensitive (Du145 and PC3) PCa cell lines [24]. The 
murine cell line TRAMP-C1 (derived from a TRAMP 
tumor) was less sensitive than the human cell lines, both 
to docetaxel and APIM-peptide. However, an increased 
efficacy in the combination group compared to docetaxel 
alone was seen in all four cell lines (Figure 2). 
To further explore the molecular mechanisms of 
the APIM-peptide induced increase in docetaxel efficacy, 
we concentrated on the three human PCa cell lines, 
and analyzed changes in gene expression under similar 
treatment regimes. Principal component analysis (PCA) 
showed that the largest variation in gene expression 
patterns was attributed to differences between the three 
human cell lines, rather than differences between the 
treatments (Figure 3A). The androgen-sensitive LNCaP 
cell line was the main contributor to the variation, while 
the androgen-insensitive Du145 and PC3 cell lines 
had more similar expression patterns. While the data 
points were clustered for LNCaP cells, a larger spread 
was observed for Du145, and especially for PC3 cells. 
However, the largest variations within the cell lines 
were attributed to the different replicas. By correcting 
for replica variations, we looked for differences in gene 
Figure 2: APIM-peptide further reduces the growth of docetaxel-stressed prostate cancer cells. Percentage viable 
TRAMP-C1, PC3, Du145, and LNCaP cells relative to untreated cells (100%). Viability measured by MTT assay after continuous exposure 
from day 0 until day 4 to APIM-peptide (14 µg/mL and 24 µg/mL, green circles)), docetaxel (0.6 ng/mL, 1.3 ng/mL and 2.5 ng/mL, blue 
triangles or crosses) or the corresponding combinations of APIM-peptide and docetaxel (black squares). The doses shown were the lowest 
doses of each agent that had effect as single agents, or displayed an enhanced effect when combined. Mean ± S.E.M. from three independent 
biological replicas are plotted. Significant differences between the combination and docetaxel groups were calculated by a one sided non-
parametric Wilcoxon Sign Rank Test, and are marked with *. 
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expression between the treatment groups in Du145 and 
PC3 cells (Figure 3B). In Du145 cells, vehicle and APIM-
peptide treatments were separated from docetaxel and 
combination treatments, while in PC3 cells each treatment 
was grouped more separately, indicating differences 
between treatment groups on a gene expression level. 
No significant differentially expressed (DE) genes 
(relative to untreated control) were common across all 
three combination treated cell lines. By excluding LNCaP, 
however, several DE genes were shared between PC3 and 
Du145 cells. While the APIM-peptide as single drug did 
not alter gene expression, clear effects of the docetaxel and 
combination treatments could be detected (Figure 3C, left 
panel). However, looking at the changes in the PC3 and 
Du145 cell lines separately, it is clear that the PC3 cell line 
responded more to the APIM-peptide alone than Du145 
(Figure 3C). Viability of PC3 was also more affected than 
Du145 at 24 hours by the APIM-peptide single treatment 
(Figure 2). 
The APIM-peptide in combination with docetaxel 
affects the expression of multiple genes in both Du145 
and PC3 cells that are not influenced by docetaxel as a 
single agent. Interestingly, several of the affected genes 
are commonly dysregulated in PCa, a few selected 
genes are shown in Table 1, and a comprehensive list is 
shown in Supplementary Table 1. For example, the drug 
combination, but not single treatments, downregulated 
expression of RPS6KA2, LY6E, NUSAP1, NUAK2 
and PAICS, five genes reported to promote PCa 
development and progression [25–31]. Additionally, the 
drug combination upregulated PINK1, IRF1, PPP1R15A, 
CRABP2, SCRN1, LIMA1, and TGFBI; all genes 
associated with tumor suppression functions in PCa [32–
41]. These changes could be contributing factors to the 
increased anti-cancer effect observed when combining 
APIM-peptide with docetaxel in the TRAMP-model. 
Functional enrichment analysis of the DE genes by the 
combination treatment found in both cell lines (grey circle 
in Figure 3C) did not point towards one specific cellular 
response/pathway, but showed that genes involved in 
multiple cellular responses, including responses to stress 
and DNA repair, were affected (Supplementary Table 2).
Combining APIM-peptide with docetaxel alters 
cellular signaling and increases apoptosis in 
prostate cancer cell lines
Several proteins in the PI3K/Akt and MAPK 
pathways contain the APIM sequence and the APIM-
peptide affects the activation of these pathways during 
stress [13]. These signaling pathways are important 
regulators of cell proliferation and apoptosis, therefore 
we next examined whether APIM-peptide alone, or in 
combination with docetaxel, altered apoptosis, cell cycle, 
and central kinases. We detected an increased level of 
apoptotic (Annexin V-positive, A) cells in both PC3 and 
Du145 cultures treated with APIM-peptide as a single 
agent, while the fractions of necrotic (PI-positive, N) cells 
were unchanged (results from contour plots are given as 
numbers in Figure 4A). Combination of docetaxel and 
APIM-peptide increased the fraction of both apoptotic 
and necrotic cells compared to the single treatments. The 
cumulative percentage of dead cells (A + N) were 33% and 
41% in Du145 and PC3, respectively, thus approximately 
an increase of 10% relative to single agent treatments 
and 20% relative to untreated control. APIM-peptide 
treatments did not affect the cell cycle distribution in any 
of the cell lines tested, neither alone nor in combination 
with docetaxel. Docetaxel alone, on the other hand, 
strongly affected cell cycle distribution and/ or the cellular 
DNA content (G2/M peak increased) in accordance with 
its mode of action (Figure 4A). 
In general, the changes in kinases and apoptotic 
factors detected by western analysis were small and for 
the most part not significant, however some trends could 
be observed. APIM-peptide as a single agent did not affect 
the level or activation of the signaling proteins tested 
(Figure 4B), which is in accordance with small changes in 
gene expression after treatment with APIM-peptide alone 
(Figure 3C and ArrayExpress, E-MTAB-4858). When 
combined with docetaxel, however, an increase in ERK1 
and 2 phosphorylation was observed relative to untreated 
control. Also, a tendency towards reduced p38 levels in 
the combination treated cells compared to docetaxel alone, 
and reduced phosphorylation of S6K, acting downstream 
of Akt, was observed in two out of three biological replicas 
in both cell lines (Figure 4B). Flow cytometry analysis 
indicated that APIM-peptide treatment increased the levels 
of apoptosis, so we also examined the extracts for the 
apoptotic markers cleaved-PARP and caspase 3. Reduced 
full-length caspase 3 and increased levels of cleaved-
PARP were observed in most replicas of docetaxel and 
combination treated cells in both cell lines. In summary, 
these results identified some changes in proteins important 
for apoptosis and cellular signaling in the combination 
treated cells, not seen or seen at a lower level in the single 
agent treated cells. 
DISCUSSION
There are limited treatment options available for 
patients with PCa progressing after docetaxel treatment. 
Prednisone in combination with carbazitaxel may be the 
most promising option and is suggested to slightly increase 
the survival of these patients; it is however, associated with 
increased toxicities [42–44]. To address new treatment 
options we monitored PCa regrowth in the TRAMP model 
following treatment with a combination of docetaxel and 
a peptide targeting PCNA. TRAMP mice as young as 10 
weeks of age display androgen-insensitive characteristics 
[23], and the mice used in this study (25–28 weeks old) 
are therefore representative of androgen-insensitive PCa. 
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Analysis of two human androgen-insensitive cell lines 
revealed initial changes in gene expression, apoptosis, 
and cellular signaling that supported the reduced regrowth 
detected in combination treated mice.
Development of drug resistance to both 
chemotherapeutics and targeted therapies are a major 
problem; combining targeted drugs with chemotherapy 
or targeting multiple signaling pathways simultaneously, 
have been suggested to combat this problem [45]. 
Given PCNA’s role as a scaffold protein affecting 
multiple signaling pathways involved in regulation of 
metabolism, apoptosis, DNA repair and cell cycle, and its 
overexpression in several cancers, PCNA has emerged as 
a potential target in cancer therapy [6, 7]. PCNA interacts 
with numerous proteins via its two PCNA interacting 
motifs, the PIP-box and APIM, which have overlapping 
binding sites on PCNA [17, 21]. Multilayered regulatory 
mechanisms determine which proteins interact with PCNA 
Figure 3: Response to drug treatment is cell-line specific, and combination of APIM-peptide with docetaxel modifies 
gene expression. Microarray analysis on PC3, Du145 and LNCaP human prostate cancer cells treated with APIM-peptide (14 µg/
mL APIM-peptide, green), docetaxel (1.3 ng/mL (Du145 and LNCaP) or 2.5 ng/mL (PC3), blue) or the combination of these (black) for 
24h (n = 3 for each treatment of each cell line). Principal component analysis (PCA) identifies the most pronounced variation modes in 
the data by combining the original data variables (here genes) into more condensed variables, termed principal components. PCA plots 
of differentially expressed (DE) genes from all treatments relative to untreated (n = 9 for all cell lines: 3 biological replicas, 3 treatment 
groups). PCA displaying general differences between (A) PC3 (brown), Du145 (purple) and LNCaP (orange) cell lines, (B) treatment 
groups in Du145 and PC3 cells after correction of replica variations. (C) Venn diagram of number of DE genes significantly upregulated 
(red) or downregulated (blue) in each treatment group relative to untreated control common in both PC3 and Du145 cells (left panel) or 
separately in Du145 cells (middle panel) and PC3 cells (right panel) (n = 6, 3 biological replicas for each cell line).
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at a given time. This includes affinity driven competition, 
posttranslational modifications (PTMs) on PCNA or the 
PCNA binding proteins, half-life/ stability of proteins 
and the context of the PCNA complexes, e.g. repair vs. 
replication, nuclear vs. cytosolic and normal growth vs. 
stress situations. Different PIP-box variants have up to 700 
fold different affinity for unmodified PCNA in absence 
of DNA (reviewed in [7, 46, 47]). Affinity differences 
between APIM consensus variants are also likely, but 
APIM variants have low affinity towards PCNA involved 
in replication, as stable cells overexpressing APIM-
peptide are viable and proliferate normally, while PIP-box 
expressing cells die. APIM-peptide overexpressing cells 
are however, hypersensitive to cellular stress [16, 48]. 
Normal cells are largely unaffected by the peptide both in 
vitro and in vivo [13, 21]. In agreement with low affinity 
for PCNA involved in replication we see no/ low effects 
on the cell cycle for APIM-treated cells in Figure 4A. 
The APIM-peptide therefore seems to mainly impair 
PCNA scaffold functions important for cellular stress 
mechanisms. 
Enhancing the efficacy of docetaxel if combined 
with the APIM-peptide could reduce the dose needed, 
reducing the discomfort for the patients and potentially 
extending the duration of chemotherapy. It is challenging 
to pinpoint the most prominent pathway that is impaired 
by the combination treatment in TRAMP-mice as it 
is likely that a multitude of pathways are affected. In 
addition, because these tumors occur spontaneously, 
one explanation does not necessarily fit for all of the 
mice, or even for all the tumor cells within one tumor. 
Nevertheless, gene expression data from the two 
androgen-insensitive cell lines gave some indications 
as to why the combination therapy had an increased 
anti-cancer effect in the TRAMP model. RPS6KA2, 
one of the genes found to be downregulated only in 
combination treated cells, encodes a serine/threonine 
kinase acting downstream of MAPK and Akt. Previous 
studies have described RPS6KA2 as a diagnostic PCa 
marker [25] and it contains one out of eleven single 
nucleotide polymorphisms (SNPs) associated with PCa 
risk [49]. Furthermore, RPS6KA2 displayed increased 
expression in PCa tissue compared to normal tissue, 
and inhibition lead to decreased proliferation of PCa 
cells [25]. Synthetic lethality between RPS6KA2 and 
erlotinib (EGFR inhibitor) is shown in PCa, supporting 
extensive crosstalk between MAPK and Akt pathways 
in PCa, and illustrates the clinical potential for 
combinatory treatments affecting these pathways [50]; 
these pathways are also affected by the APIM-peptide. 
Interestingly, a recent publication on PCa progression 
has pinpointed the importance of NUSAP1, one of the 
genes downregulated by the combination treatment [29]. 
NUSAP1 is an important microtubule-associated protein 
Table 1: APIM-peptide in combination with docetaxel affects gene expression of genes commonly 
dysregulated in prostate cancer
Downregulated 
PC3 Du145





Ribosomal Protein S6 Kinase 90 kDa Polypeptide 2 (RPS6KA2) [25, 49] 219 -0.2 0.016 489 - 0.2 0.020 
Nucleolar And Spindle Associated Protein 1 (NUSAP1) [29] 57 -0.2 0,0018 390 -0.2 0.0150
Lymphocyte Antigen 6 Complex, Locus E (LY6E) [27] 83 - 0.2 0.004 684 - 0.2 0.028 
NUAK Family, SNF1-like Kinase 2 (NUAK2) [28] 410 - 0.1 0.032 777 - 0.1 0.034 
Phosphoribosylaminoimidazole Carboxylase And 
Phosphoribosylaminoimidazolesuccinocarboxamide Synthase 
(PAICS)
[31] 94 -0.1 0.0049 949 -0,2 0.0481
Upregulated 
PTEN Induced Putative Kinase 1 (PINK1) [32, 61] 141 0.2 0.009 162 0.2 0.003 
Interferon Regulatory Factor (IRF1) [33, 62] 331 0.2 0.027 301 0.2 0.010 
Protein Phosphatase 1, Regulatory Subunit 15A (PPP1R15A) [36, 63] 74 0.3 0.003 103 0.3 0.001 
Cellular Retinoic Acid Binding Protein 2 (CRABP2) [37] 188 0.2 0.014 343 0.2 0.013
Secernin 1 (SCRN1) [35] 12 0.2 0.0002 217 0.2 0.006
LIM Domain and Actin Binding 1 (LIMA1) [41] 98 0.2 0.005 214 0.2 0.006
*Transforming Growth Factor Beta Induced 68 kDa (TGFBI) [39] 10 0.5 0.00005 101 0.4 0.001
Selection of significant (p < 0.05) differentially expressed (DE) genes from microarray analysis found in both Du145 and PC3 cells (n = 6) treated with 
the combination of APIM-peptide (14 µg/mL) and docetaxel (1.3 ng/mL (Du145) or 2.5 ng/mL (PC3)). The selected genes listed were only found in the 
combination treatment, and are commonly dysregulated in human prostate cancer. The downregulated genes listed are reported to be tumor promoting and 
the upregulated genes listed are reported to be tumor suppressing in given publications. The complete list of all DE genes is presented in Supplementary 
Table 1. FC = Fold change. *More enhanced (as described by p-value and rank) in combination than docetaxel treatment.
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Figure 4: APIM-peptide increases the effects of docetaxel on apoptosis and cellular signaling. (A) Cell cycle analysis and 
fraction of apoptotic (A) vs necrotic (N) cells (values from contour plots are given). (B) Relative expression of phosphorylated Akt, ERK1, 
ERK2, S6K, and p38, cleaved-PARP, and caspase 3. For all experiments, PC3 and Du145 cells were treated with APIM-peptide (14 µg/
mL, green), docetaxel (2.5 ng/mL: PC3; 1.3 ng/mL: Du145; 5 ng/mL, blue) and the combination of these (black) for 24 hours prior to the 
analysis. The protein levels (B) were adjusted for loading differences (β-tubulin) and normalized against untreated cells, and additionally 
for total protein levels for the phosphorylated proteins. Data are from three biological replicas (different symbols represents extracts 
acquired on different days). Statistically significant differences (*p < 0.05) were calculated by a Kruskal-Wallis H test, and a post-hoc 
Dunn’s test was used to determine which groups this applied to.
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[51]; its role in PCa is suggested to be via induction of 
FAM101B that modulates cell shape and is involved in 
the TGF-β pathway promoting tumor invasion. NUSAP1 
knockout resulted in reduced migration in PCa cell lines, 
reduced tumor volume in PCa xenografts, and a NUSAP1 
knockdown gene expression signature correlated with 
better outcome in patient PCa samples [29]. Moreover, 
NUSAP1 is the only gene that appears in two out of 
the three commercially available gene expression 
signatures currently used for assessing aggressive PCa 
[52, 53] and (Rye et al, unpublished). Another frequently 
overexpressed gene in PCa, LY6E, was revealed as 
downregulated by microarray analysis in combination 
treated cells [27]. Increased expression of LY6E, an 
interferon inducible gene, is shown to be linked to poor 
survival in multiple cancers. LY6E promotes signaling via 
the TGF-β pathway leading to increased drug resistance, 
PDL1 and CTLA4 expression, and immune escape in 
breast cancer [54]. The APIM-peptide is shown to affect 
several of the downstream mediators of TGF-β such as the 
ERKs, p38, TNF-α and PI3K/Akt, as well as interferon 
which act upstream of LY6E [13, 55]. Microarray analysis 
also revealed a downregulation of two other frequently 
overexpressed genes in PCa, NUAK2 and PAICS 
[28, 31]. NUAK2 (SNARK) is a NF-kappaB-regulated 
anti-apoptotic gene [56], while PAICS is a de novo purine 
biosynthetic enzyme. A recent study identified PAICS 
as essential for PCa cell growth and progression; its 
knockdown caused reduced PCa growth both in vitro and 
in vivo, thus PAICS was indicated as an important target 
in PCa treatment [31]. The downregulation of these genes 
could be related to the APIM-peptide’s ability to modulate 
members of the upstream pathways, such as MAPKs and 
PI3Ks.
Several interesting genes were also found to be 
upregulated by the combination treatment. The exact 
molecular mechanism behind the increased expression 
is not known, but cellular signaling networks are highly 
dynamic and the ripple effects extensive. In any case, 
a reduced expression of these genes is reported to be 
associated with increased cancer cell growth and/or 
invasiveness (see references in Table 1). Therefore, an 
increased expression of these genes may support the 
reduced re-growth observed in the TRAMP model.
In summary, the effects observed in growth assays, 
western, flow cytometry, and gene expression analysis 
support the increased efficacy seen in the TRAMP mouse 
model when docetaxel is given in combination with the 
APIM-peptide. Multiple proteins involved in cellular 
signaling, including kinases, phosphatases, and ubiquitin 
ligases, contain the APIM or the PIP-box PCNA binding 
sequence, thus indicating a central role for PCNA as 
a cytosolic scaffold [16]. Small changes in multiple 
pathways are expected when inhibiting the abilities of 
PCNA-interacting proteins to bind to their scaffold, 
which is likely to be the reason for the modified docetaxel 
response observed in combination with the APIM-peptide. 
Even with modest changes, if the combination of the 
APIM-peptide and docetaxel could result in the same 
clinical outcome using a lower docetaxel dose, then there 
could be noticeable improvements to patient quality of life 
from reduced docetaxel-induced side effects. In support 
of this, in a pilot study in the TRAMP model using a low 
dose of docetaxel (0.5 mg/kg versus 3 mg/kg in the main 
study) a significant increase in initial response in the 
combination treated group compared to docetaxel single 
treated group was observed (Supplementary Figure 1). 
In all our experiments, we treated the mice for only one 
week; in future experiments, however, it would be of 
interest to administer repeated weekly treatments with low 
dose docetaxel in combination with the APIM-peptide to 
look at long-term effects.
Our results suggest that APIM-peptide in 
combination with docetaxel downregulated several genes 
considered to be therapeutic targets, and upregulated 
several genes with a protective role against PCa. 
Signaling and gene expression regulation, however, 
are dynamic processes; the western, flow, and gene 
expression analysis were only performed 24 hours 
after treatment, thus limiting our study to a snapshot. 
Nevertheless, the results clearly demonstrate altered 
cellular processes, which could explain the regrowth 
characteristics that we observed in the TRAMP model. 
For a more complete understanding of the mechanisms 
underlying the increased anti-cancer efficacy observed 
by combining APIM-peptide with docetaxel, additional 
studies and verifications are needed. 
In conclusion, our preclinical data supports that 
APIM-peptide targeting PCNA has the potential to 
improve the non-mitotic effects of docetaxel. Despite 
the intrinsic heterogeneity within the TRAMP model, 
as within PCa patients, APIM-peptide in combination 
with docetaxel had a marked effect in vivo. Thus, this 
combination has a potential for clinical translation.
MATERIALS AND METHODS
Animals and ethics
Animal care and experiments were carried out in 
accordance with Norwegian and EU guidelines for care 
and use of laboratory animals, and were approved by the 
Norwegian National Animal Research Authority and the 
Norwegian Food Safety Authority (FOTS application 
6681). The colony of TRAMP mice used as model 
organism in all animal experiments, were genetically 
modified from C57BL/6 mice (Jackson Labs, USA) and 
established in-house (NTNU, Norway). Genotyping 
was performed by PCR. The animals were kept in a 
standardized environment, and monitored for general 
health status and body weight for the duration of the 
experiments.
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In vivo study design 
The mice were recruited to the study at 25–28 
weeks old, and mice exhibiting poorly-differentiated 
tumors on the first magnetic resonance imaging (MRI) 
exam were excluded from the study [57]. The animals 
were randomly distributed into three treatment groups: 
(a) vehicle (0.14% (V/V) ethanol in PBS, day 0, 1, and 
2, n = 7), (b) docetaxel (3 mg/kg, one dose, day 0, n = 7) 
and (c) docetaxel (3 mg/kg, one dose, day 0) + APIM-
peptide (6 mg/kg, three doses, day 0, 1, and 2, n = 5). 
In accordance with the reduction principle of the 3Rs 
(reduce, refine, replace), we reduced the number of mice 
in the combination treatment group; we anticipated a 
higher tumor burden in the vehicle and docetaxel groups, 
thus increasing the likelihood of earlier termination and 
the requirement of more animals. An APIM-peptide 
single drug treatment group was not included in the 
study because previous studies have demonstrated that 
APIM-peptide as a single agent did not reduce tumor 
growth in vivo [21, 22]. Treatments were performed by 
intraperitoneal injections. Prostate growth was assessed 
by MRI at day 7, 21 and 28 after treatment. The animals 
were terminated at day 28 after treatment, or when MRI 
revealed an unacceptable tumor burden. 
MRI
MRI was performed on a 7T scanner (Biospec 
70/20 Avance III, Bruker Biospin MRI, Ettlingen, 
Germany) with a volume resonator (86 mm diameter) 
for RF transmission and a phased array mouse heart 
surface coil for reception. Mice were anesthetised (~2% 
isoflurane in medical air with 36% O2) for the duration 
of the MRI scan and positioned on the scanner bed in a 
prone position. Breathing motion in the pelvic region was 
reduced by firmly securing the mouse to the scanner bed 
with adhesive tape across its lower back. The respiration 
rate was monitored (SA Instruments, USA) and the body 
temperature was kept (37°C) by circulating warm water 
through the bed. For full details on the MRI imaging 
sequences and parameters, see [57], in brief, the following 
imaging sequences were performed: Low-resolution T2 
weighted (LR-T2W) images were acquired in axial and 
coronal planes using a RARE spin echo sequence to 
check correct positioning of the mouse. High-resolution 
T2W (HR-T2W) images were acquired in the axial plane 
using a RARE spin echo sequence. Diffusion weighted 
(DW-MRI) images were acquired using a Stejskal-Tanner 
prepared multi-shot EPI sequence with b-values = 0, 100, 
200, 400, 800 along three orthogonal gradient directions 
over the same region of the mouse as HR-T2W images to 
allow for image registration. ADC maps were calculated in 
MatLab (MathWorks, Natick, MA) by voxelwise fitting of 
the signal (S) averaged over all gradient directions using 
a monoexponential model for all b-values according to 
S(b)=S0exp(–b ADC), where S0 is the signal intensity for 
b0.
MRI assessment of prostate volume
Whole prostate volumes (including ventral, lateral 
and dorsal lobes) from each mouse were calculated by 
manually-drawn ROIs based on HR-T2W images using 
OsiriX (Pixmeo SARL, Switzerland), employing b800 
DW-MR images as a reference to discriminate prostate 
from seminal vesicle (SV), according to the method 
described in [57]. Data are reported as mean ± S.E.M. 
and statistical significance between groups was calculated 
using an unpaired, two-tailed Student’s t-test (p < 0.05).
Treatment agents
APIM-peptide (ATX-101), a 25 amino acid cell 
penetrating peptide containing the APIM sequence (APIM 
Therapeutics, Norway) [21] and docetaxel (Actavis, 
Iceland).
Cell lines
One PCa cell line isolated from TRAMP mice 
(TRAMP-C1, ATCC-CRL-2730) and three human PCa 
cell lines, PC3 (ATCC CRL-1435, androgen-insensitive, 
high metastatic potential) Du145 (ATCC HTB-81, 
androgen-insensitive, moderate metastatic potential), and 
LNCaP (androgen-sensitive, low metastatic potential) 
were used for the in vitro studies. LNCaP cells were kindly 
provided by Senior Engineer Berit Størdal, Department of 
Molecular Medicine, Norwegian University of Science 
and Technology, Norway. All cell lines were grown in 
DMEM or RPMI-1640 medium (Sigma-Aldrich, UK) 
supplemented with fetal bovine serum (10%, Sigma-
Aldrich, Norway), amphotericin B (2.5 µg/mL, Sigma-
Aldrich, MO, USA), L-glutamine (2 mM, Sigma-Aldrich, 
MO, USA) and penicillin (100 units/mL)-streptomycin 
(0.1 mg/mL) (Gibco, NY, USA). Cells were cultivated in 
a humidified atmosphere (95% air, 5% CO2, 37ºC). 
Cell viability assay 
Cell growth over time was measured using the 
3-(4.5-Dimethylthiazol-2-yl)-2.5 diphenyl-tetrazolium 
bromide (MTT, Sigma-Aldrich, MO, USA) assay similarly 
as in [16]. Cells were seeded in 96-well plates (3,000 
cells/well) and continuously exposed to APIM-peptide 
(14 µg/mL APIM-peptide for Du145, PC3 and LNCaP, or 
24 µg/mL for TRAMP-C1 and docetaxel (0.6 ng/mL for 
Du145 and LNCaP, 1.3 ng/mL for PC3, or 2.5 ng/mL for 
TRAMP-C1) until harvest at day one, three, and four. The 
ratio of viable cells in individual replicas of docetaxel and 
APIM-peptide + docetaxel treated cells versus untreated 
cells were log transformed with base 2. The resulting 
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values reflecting the change of docetaxel + APIM-peptide 
relative to docetaxel only were subjected to one sided non-
parametric Wilcoxon Signed Rank Test as implemented in 
MATLAB R2015a (MathWorks Inc.), in order to check 
if the combination treatment further reduced the viability 
compared to docetaxel alone.
Cell treatments for flow cytometry analysis, 
western blot and microarray
Cells were seeded in plates (3 million cells/15 cm 
plate) the day before treatment; APIM-peptide (14 µg/mL 
for Du145, PC3 and LNCaP, or 24 µg/mL for TRAMP-C1) 
(same dose as in the MTT assay) and docetaxel (1.3 ng/
mL for Du145 and LNCaP, 2.5 ng/mL for PC3, or 5.0 ng/
mL for TRAMP-C1) (2× doses compared to MTT assay, 
see below) were given as single agents or in combination 
(three treatment groups and one untreated control group 
per cell line). Twice as many cells/ area were used 
compared to the MTT assay and experiments showed 
that twice as high docetaxel dose was needed to obtain 
the same effect with respect to viability, while the same 
APIM-peptide dose gave similar effects. The cells were 
exposed continuously for 24 hours before harvest. Three 
biological replicas started on different days (n = 3) were 
prepared for all groups of each cell line.
Cell extracts
Cell extracts were prepared as previously described 
[13]. Briefly, cells were collected, resuspended and 
incubated in lysis buffer (1.5 h, 4ºC), followed by 
sonication (2 min, 2.5 output control, 20% duty cycle) 
and centrifugation (10 min, 4ºC, 13 600 rpm). The 
supernatants were collected as total cell extract. 
Flow cytometry analysis 
The fraction of apoptotic cells and the cell cycle 
distribution were analyzed. 1 million live cells were 
labeled with the Dead Cell Apoptosis Kit (Molecular 
Probes) according to the manufacturer’s protocol. Briefly, 
the cells were resuspended in 100 µl annexin-binding 
buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, 
pH 7.4), supplied with 5 µl of Annexin V Alexa Fluor® 488 
and 1 µl of Propidium Iodide (PI; 0,1 mg/ml), incubated 
for 15 minutes at room temperature and analyzed on a 
BD FACS Canto flowcytometer (BD Biosciences). Cells 
stained with Annexin V Alexa Fluor® 488 and PI were 
excited with a blue laser (488 nm), and the Annexin V 
Alexa Fluor® 488 fluorescence and the PI fluorescence 
were detected in the FITC (530/30; 502LP) and the PE 
(585/42; 556LP) channel, respectively. The fraction of 
apoptotic (A) and necrotic (N) cells was determined by 
using the FlowJo, LLC software (USA), and the numbers 
are given in the histograms showing DNA contents 
(described below). Parallel samples of cells were fixed in 
ice-cold 100 % methanol and stored at 4ºC until cell cycle 
analysis. The cells were washed with cold phosphate-
buffered saline (PBS) and incubated with 200 μl of DNase-
free RNAse A (Sigma) in PBS (100 μg/ml) for 30 min 
at 37ºC before DNA staining with 200 μl of PI (Sigma) 
(50 μg/ml) at 37ºC for 30 min. Cell cycle analyses were 
performed by using a BD FACS Canto flowcytometer (BD 
Biosciences). PI stained cells were excited with the blue 
laser (488nm), and the PI fluorescence was detected in the 
PE channel. Cell cycle fractions were determined by using 
the FlowJo, LLC software.
Western blot analysis
Cell extracts (50 µg) were added to LDS loading 
buffer (1×) and DTT (0.1 M) and incubated (10 min, 
70ºC) to reverse cross-links. Proteins were separated by 
electrophoresis (10% Bis-Tris gels, NuPAGE, Invitrogen, 
CA, USA) and subsequently transferred to polyvinylidene 
fluoride membranes (Immobilon, Millipore, Ireland). 
The membranes were blocked in blocking buffer (5% dry 
milk in PBS) before incubation with primary antibodies 
against Akt (Cell Signaling Technology, #4691, MA, 
USA), Phospo-Akt (P-Akt, Ser473, Cell Signaling 
Technology, #4060, MA, USA), ERK1/2 (ERK, Santa 
Cruz Biotechnology, sc-93-G, TX, USA), Phospho-
ERK1/2 (P-ERK, Thr202/Tyr204, #4370, Cell Signaling 
Technology, MA, USA), p70 S6 Kinase (S6K, Cell 
Signaling Technology, #2708, MA, USA), Phospho-
S6K (P-S6K, Thr389, Cell Signaling Technology, 
#9206, MA, USA), p38 (Abcam, ab31828, UK), cleaved 
PARP (Abcam, ab4830, UK), Caspase 3 (Cell Signaling 
Technology, #9662, MA, USA), β-tubulin (Abcam, 
ab6046, UK) and β-actin (Abcam, ab8226, UK). The 
fluorescently labelled secondary antibodies goat α-rabbit 
680RD, goat α-mouse 800CW and donkey α-goat 800 
CW (all Li-Cor Biosciences, UK) were used for protein 
detection. All antibodies were diluted in blocking buffer 
(5% dry milk in PBS with 0.1% Tween 20). The proteins 
were visualized in Odyssey infrared imaging system (LI-
COR Biosciences, UK) and quantified in Odyssey Image 
Studio (V2.0). Protein levels were normalized against 
β-tubulin or β-actin and compared to untreated control. 
Phosphorylated proteins were additionally compared 
to the total protein levels. Data are reported as mean ± 
S.E.M. Significant differences (p <0 .05) between groups 
were calculated using a Kruskal-Wallis H test in Matlab 
(MathWorks, Natick, MA, USA) and a post-hoc Dunn’s 
test [58] was used to determine which groups were 
significantly different.
Microarray
Cells were harvested (2.5 × 106 cells) and total 
RNA extracted using the RNeasy mini kit (QIAGEN, 
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Germany). Genome-wide gene expression profiling was 
performed by using Illumina HumanHT-12 v4 Expression 
BeadChip (Illumina Inc. CA, USA), providing a coverage 
of more than 24,000 annotated genes (47,231 probes 
corresponding to 1 to 3 probes per gene) including well 
characterized genes and splice variants. Using the Illumina 
TotalPrep RNA Amplification Kit from Ambion (Thermo 
Fisher Scientific Inc. MA, USA), extracted total RNAs 
(500 ng) were converted to cDNAs and subsequent biotin 
labeled single-stranded cRNAs. Prior to cRNA synthesis 
the integrity of the total RNA was analyzed using the 
Agilent 2100 bioanalyzer with the Agilent RNA 6000 
Nano Kit. The concentration of cRNA was measured with 
NanoDrop 8000 UV-Vis Spectrophotometer instrument 
(Thermo Scientific, DE, USA) and normalized (150 
ng/µl). Biotin labeled cRNAs (1.5 µg) were hybridized 
overnight to the HumanHT-12 Expression BeadChips. 
Subsequent steps included washing, streptavidin-Cy3 
staining and scanning of the arrays were performed on 
an Illumina HiScan instrument. Probe and intensity data 
were exported from Illumina’s proprietary software. The 
microarray experiments are minimum information about 
a microarray experiment (MIAME) compliant and have 
been deposited in the ArrayExpress database (http://
www.ebi.ac.uk/arrayexpress/) under accession number 
E-MTAB-4858.
Gene expression analysis
Prior to differential expression analysis, probes 
with low detection (p < 0.1) were filtered, data log2- 
transformed, and quantile normalized. Log2-transformed 
expression values for all samples (n = 36 (four groups: 
Docetaxel, APIM-peptide, combination, untreated), 
three biological replicas conducted on separate days for 
three cell lines) were subjected to principal component 
analysis (PCA) [59]. PCA identifies the most pronounced 
variation modes in the data by combining the original 
data variables (here genes) into more condensed variables 
termed principal components. To emphasize differences 
between the different groups, baseline expression level 
differences due to variation between cell-lines and 
biological replicates were minimized by subtracting the 
mean expression value from each subset of replicates 
in each cell line (nine subsets in total), which was done 
for each gene. Differentially expressed (DE) genes were 
calculated by the limma package in R, and identified 
p-values were adjusted for multiple hypothesis testing 
using Benjamini and Hochberg false discovery rate 
(FDR) [60]. Gene changes specific to the combination 
treatment were defined as those DE (p < 0.05) in the 
combination treatment of both Du145 and PC3, but not 
DE when treated with docetaxel in neither Du145 nor 
PC3. In addition, genes with increased rank (by p-value) 
and fold-change (FC) in the combination treatment of both 
Du145 and PC3 compared to docetaxel were identified by 
manual inspection of the ranked gene lists, and defined as 
enhanced by the combination treatment. 
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